Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
cf-bDNA costs $89,600 per quality-adjusted life year gained, with alternatives less costly and more effective
Restaging MRI Can Predict Survival With Rectal Cancer
Findings can save some lower-risk patients surgery after chemo, radiation
Guideline-Concordant Care Less Likely With Non-Hispanic Black Race
Findings seen in older patients with breast cancer; non-Hispanic Black patients also less likely to have timely initiation of treatment
Many Seniors at Risk for Financial Precarity From Cost of Hospital Stay
Financial precarity more prevalent among Black and Hispanic versus White, those with less versus more than high school education
ACS: Many Cancer Patients Face Lasting Financial Difficulties
Patients with cancer have higher rates of total collections, medical collections, and bankruptcy
Medicaid Expansion Increases Guideline-Concordant Treatment for Breast Cancer
Increase seen in receipt of guideline-concordant treatment for women newly diagnosed with HR-negative, HER2-positive breast cancer
Higher Heathy Eating Index Score Beneficial in Prostate Cancer
Higher Healthy Eating Index score linked to significantly lower risk for grade reclassification in men undergoing active surveillance
Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
Protracted low-dose exposure to ionizing radiation linked to mortality due to certain hematologic malignancies
FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer
Vyloy is the first and only CLDN18.2-targeted therapy approved in the United States
